rare kidney disease

DEER PARK, Ill., August 5, 2026 Eton Pharmaceuticals has licensed the U.S. rights to ASN-001 (timolol topical gel) from...

Glasgow, Scotland, August 5, 2026 Mironid has successfully raised $46 million in a Series B financing round to accelerate...

GLASGOW, Scotland – June 6, 2026 AstraZeneca’s rare disease division, Alexion, has reported positive interim Phase III results for...

SAN DIEGO, California, USA, June 2, 2026 Travere Therapeutics has significantly expanded its rare kidney disease pipeline through an...

San Diego, California | April 13, 2026 Travere Therapeutics, Inc. has announced that the U.S. Food and Drug Administration...

BASEL, Oct. 16, 2025 — Novartis announced positive final Phase III results from its APPLAUSE-IgAN trial, confirming that Fabhalta®...

MONMOUTH, N.J., Sept. 18, 2025 A new investigational therapy, JD-004, has received Orphan Drug Designation (ODD) from the U.S. Food...